<- Go Home
Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren’s disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
Market Cap
$4.2B
Volume
1.3M
Cash and Equivalents
$521.9M
EBITDA
-$486.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$29.49
52 Week Low
$12.72
Dividend
N/A
Price / Book Value
7.97
Price / Earnings
-8.41
Price / Tangible Book Value
7.97
Enterprise Value
$3.6B
Enterprise Value / EBITDA
-7.48
Operating Income
-$487.1M
Return on Equity
95.93%
Return on Assets
-55.42
Cash and Short Term Investments
$521.9M
Debt
N/A
Equity
$519.7M
Revenue
N/A
Unlevered FCF
-$269.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium